A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside

Blood

Volumn 119, Issue 5, 2012, Pages 1200-1207

  McDermott, Sean P ^a,b,c   Eppert, Kolja ^a,b,c   Notta, Faiyaz ^a,b,c   Isaac, Methvin ^d   Datti, Alessandro ^e,f   Al awar, Rima ^d   Wrana, Jeff ^e   Minden, Mark D ^g   Dick, John E ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF PERUGIA   (Italy)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE DERIVATIVE; CAMPTOTHECIN; CD34 ANTIGEN; CD38 ANTIGEN; CYTARABINE; DAUNORUBICIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; KINETIN RIBOSIDE; METFORMIN; MITOXANTRONE; PACLITAXEL; PARTHENOLIDE; PROTEIN BCL 2; PROTEIN P53; RAPAMYCIN; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLAST CELL; CANCER CELL CULTURE; CANCER STEM CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; HEMATOPOIETIC STEM CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA STEM CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VALIDATION PROCESS;

EID: 84856596426     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-330019     Document Type: Article

References (48)

1. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645-648. (Pubitemid 24067706)
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737. (Pubitemid 27298715)
3. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immun. 2004;5(7):738-743. (Pubitemid 39023306)
4. Pearce DJ, Taussig D, Zibara K, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood. 2006;107(3):1166-1173. (Pubitemid 43156319)
5. van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11(18):6520-6527. (Pubitemid 41338990)
6. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98(24):1777-1785. (Pubitemid 46017929)
7. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009;106(33):13820-13825.
8. Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17(9):1086-1093.
9. Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315-1321. (Pubitemid 350076512)
10. Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A. 2002;99(25):16220-16225. (Pubitemid 35462776)
11. Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 2010;28(3):275-280.
12. de Grouw EP, Raaijmakers MH, Boezeman JB, et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells. Leukemia. 2006;20(4):750-754.
13. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760. (Pubitemid 44949604)
14. Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2(17):17ra9.
15. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5(1):31-42.
16. Guzman ML, Li X, Corbett CA, et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood. 2007;110(13):4436-4444. (Pubitemid 351377810)
17. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105(11):4163-4169. (Pubitemid 40720758)
18. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-term multi-lineage engraftment. Science. 2011;333(6039):218-221.
19. Warner JK, Wang JC, Takenaka K, et al. Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. Leukemia. 2005;19(10):1794-1805. (Pubitemid 41486158)
20. Barabé F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science. 2007;316(5824):600- 604. (Pubitemid 46683146)
21. Ng AP, Loughran SJ, Metcalf D, et al. Erg is required for self-renewal of hematopoietic stem cells during stress hematopoiesis in mice. Blood. 2011;118(9):2454-2461.
22. Thoms JA, Birger Y, Foster S, et al. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer. Blood. 2011;117(26):7079-7089.
23. Wilson NK, Foster SD, Wang X, et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell. 2010;7(4):532-544.
24. Kennedy JA, Barabe F, Poeppl AG, Wang JC, Dick JE. Comment on "Tumor growth need not be driven by rare cancer stem cells." Science. 2007;318(5857):1722.
25. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. Statistical practice in high-throughput screening data analysis. Nat Biotechnol. 2006;24(2):167-175. (Pubitemid 43221699)
26. Armstrong JS, Yang H, Duan W, Whiteman M. Cytochrome bc(1) regulates the mitochondrial permeability transition by two distinct pathways. J Biol Chem. 2004;279(48):50420-50428. (Pubitemid 39577860)
27. Arakawa M, Ushimaru N, Osada N, Oda T, Ishige K, Ito Y. N-acetylcysteine selectively protects cerebellar granule cells from 4-hydroxynonenal-induced cell death. Neurosci Res. 2006;55(3):255-263. (Pubitemid 43766414)
28. McDermott SP, Eppert K, Lechman ER, Doedens M, Dick JE. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood. 2010;116(2):193-200.
29. McKenzie JL, Gan OI, Doedens M, Dick JE. Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells. Blood. 2005;106(4):1259-1261. (Pubitemid 41129588)
30. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10):1167-1174. (Pubitemid 44527352)
31. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003;423(6937):255-260. (Pubitemid 40852690)
32. Wei J, Wunderlich M, Fox C, et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 2008;13(6):483-495. (Pubitemid 351763903)
33. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26. (Pubitemid 33653411)
34. Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008;112(3):568-575.
35. Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther. 2002;1(10):841-849.
36. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5(3):247-264. (Pubitemid 43336037)
37. Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene. 2008;27(50):6522-6537.
38. Jarvis MF, Yu H, Kohlhaas K, et al. ABT-702 (4-amino-5-(3-bromophenyl)-7- (6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. J Pharmacol Exp Ther. 2000;295(3):1156-1164.
39. McGaraughty S, Chu KL, Wismer CT, et al. Effects of A-134974, a novel adenosine kinase inhibitor, on carrageenan-induced inflammatory hyperalgesia and locomotor activity in rats: evaluation of the sites of action. J Pharmacol Exp Ther. 2001;296(2):501-509. (Pubitemid 32112479)
40. Kurebayashi N, Kodama T, Ogawa Y. P1,P5-Di(adenosine-5′) pentaphosphate(Ap5A) as an inhibitor of adenylate kinase in studies of fragmented sarcoplasmic reticulum from bullfrog skeletal muscle. J Biochem. 1980;88(3):871-876.
41. Cristalli G, Podda GM, Costanzi S, et al. Effects of 5′-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors. J Med Chem. 2005;48(8):2763-2766. (Pubitemid 40552908)
42. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006;94(2):195-199. (Pubitemid 43151534)
43. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-1174. (Pubitemid 32995375)
44. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008;1(1-4):27-36.
45. Eberhard Y, McDermott SP, Wang X, et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood. 2009;114(14):3064-3073.
46. Sukhai MA, Spagnuolo PA, Weir S, Kasper J, Patton L, Schimmer AD. New sources of drugs for hematologic malignancies. Blood. 2011;117(25):6747-6755.
47. Milyavsky M, Gan OI, Trottier M, et al. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell. 2010;7(2):186-197.
48. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645-659.